Selected article for: "acinar cell damage and acute pancreatitis"
Title: 2015 ACVIM Forum Research Abstract Program
  • Document date: 2015_5_27
    • ID: 3pnuj5ru_420
    Snippet: The decrease in cPLI concentrations would suggest an attenuation of acinar cell damage but evaluation of efficacy requires further controlled studies. Despite marked individual decreases, no significant anti-inflammatory or anti-fibrotic properties were identified. Oral CM therapy at doses up to 24 mg/kg/d for up to 31 days was found to be safe in dogs with suspected chronic pancreatitis, with only mild adverse effects reported. The purpose of th.....
    Document: The decrease in cPLI concentrations would suggest an attenuation of acinar cell damage but evaluation of efficacy requires further controlled studies. Despite marked individual decreases, no significant anti-inflammatory or anti-fibrotic properties were identified. Oral CM therapy at doses up to 24 mg/kg/d for up to 31 days was found to be safe in dogs with suspected chronic pancreatitis, with only mild adverse effects reported. The purpose of this study was to investigate b-hydroxybutyrate (BOHB) concentrations in dogs with acute pancreatitis (AP) and without diabetes mellitus.

    Search related documents:
    Co phrase search for related documents
    • acinar cell and AP acute pancreatitis: 1, 2, 3, 4
    • acinar cell and chronic pancreatitis: 1, 2, 3
    • acinar cell and cm therapy: 1
    • acinar cell and diabetes mellitus: 1
    • acinar cell and study purpose: 1
    • acinar cell damage and chronic pancreatitis: 1
    • acinar cell damage and cm therapy: 1
    • acinar cell damage and study purpose: 1
    • acute pancreatitis and AP acute pancreatitis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50
    • acute pancreatitis and chronic pancreatitis: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute pancreatitis and control study: 1, 2, 3, 4
    • acute pancreatitis and cpli concentration: 1
    • acute pancreatitis and diabetes mellitus: 1, 2, 3, 4, 5, 6, 7, 8
    • acute pancreatitis and study purpose: 1, 2, 3, 4, 5, 6
    • adverse effect and cm therapy: 1
    • adverse effect and control study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • adverse effect and diabetes mellitus: 1, 2, 3, 4, 5, 6, 7
    • adverse effect and efficacy evaluation: 1
    • adverse effect and mild adverse effect: 1, 2, 3, 4